Artwork

Content provided by DIA: Driving Insights to Action. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DIA: Driving Insights to Action or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

CFDA Joins ICH, Seeks Public Comment on Further Reforms

31:33
 
Share
 

Archived series ("iTunes Redirect" status)

Replaced by: DIA: Driving Insights to Action

When? This feed was archived on December 27, 2017 02:48 (6+ y ago). Last successful fetch was on December 25, 2017 22:00 (6+ y ago)

Why? iTunes Redirect status. The feed contained an iTunes new feed tag.

What now? If you were subscribed to this series when it was replaced, you will now be subscribed to the replacement series. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage episode 181997392 series 1219012
Content provided by DIA: Driving Insights to Action. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DIA: Driving Insights to Action or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In May 2017, the China Food and Drug Administration (CFDA) issued four new draft policies, the latest in a series of regulatory reforms which began in 2015 to accelerate the review and approval, and improve the quality, of new drugs and medical devices, for public comment. In June 2017, ICH and the CFDA jointly announced that CFDA had joined ICH as a Member. “CFDA is continuing to enhance the regulatory standards and regulatory system to promote innovation to improve the drug R&D ecosystem and, ultimately, to improve the access of medicines to patients,” explains pharmaceutical industry veteran Dr. Ling Su, Director and Professor at the Institute of Drug Regulatory Science at Shenyang Pharmaceutical University, and a Venture Partner at Lilly Asia Ventures, in this Global Forum podcast. “The CFDA has clearly indicated that, by joining ICH, the CFDA will comply with the rules and principles of ICH. This new development aligns very well with CFDA’s intention to become more aligned with international standards.”

  continue reading

20 episodes

Artwork
iconShare
 

Archived series ("iTunes Redirect" status)

Replaced by: DIA: Driving Insights to Action

When? This feed was archived on December 27, 2017 02:48 (6+ y ago). Last successful fetch was on December 25, 2017 22:00 (6+ y ago)

Why? iTunes Redirect status. The feed contained an iTunes new feed tag.

What now? If you were subscribed to this series when it was replaced, you will now be subscribed to the replacement series. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage episode 181997392 series 1219012
Content provided by DIA: Driving Insights to Action. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DIA: Driving Insights to Action or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In May 2017, the China Food and Drug Administration (CFDA) issued four new draft policies, the latest in a series of regulatory reforms which began in 2015 to accelerate the review and approval, and improve the quality, of new drugs and medical devices, for public comment. In June 2017, ICH and the CFDA jointly announced that CFDA had joined ICH as a Member. “CFDA is continuing to enhance the regulatory standards and regulatory system to promote innovation to improve the drug R&D ecosystem and, ultimately, to improve the access of medicines to patients,” explains pharmaceutical industry veteran Dr. Ling Su, Director and Professor at the Institute of Drug Regulatory Science at Shenyang Pharmaceutical University, and a Venture Partner at Lilly Asia Ventures, in this Global Forum podcast. “The CFDA has clearly indicated that, by joining ICH, the CFDA will comply with the rules and principles of ICH. This new development aligns very well with CFDA’s intention to become more aligned with international standards.”

  continue reading

20 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide